PharmaLex MedTech Local Affiliate Services vs bioaccess® LATAM Registration Holder

PharmaLex (Cencora) vs bioaccess®: what PharmaLex (Cencora) publishes, and when a one-country or dossier partner is enough versus the bioaccess® registration holder across Latin America.

PharmaLex (Cencora) shows up when manufacturers search for a Latin American registration holder or sanitary-registration partner. This article uses only what PharmaLex (Cencora) publishes on its own site (www.pharmalex.com/pharmalex-industry-sectors/medtech · www.pharmalex.com/pharmalex-solutions/local-affiliate-services), then compares it with the multi-country subscription from bioaccess®. It is a practitioner comparison, not a teardown.

What PharmaLex (Cencora) publishes

PharmaLex, part of Cencora, is a global regulatory consultancy that says it has 60+ offices in 32 countries. Its MedTech page says it arranges authorized-representative services in "multiple markets" and manages the product licenses, and its local-affiliate page names emerging Latin American markets "such as Brazil and Mexico." The public pages do not list INVIMA, ANMAT, ISP or DIGEMID holder services one by one, and much of the MedTech content is EU MDR/IVDR work.

PharmaLex (Cencora) vs bioaccess®

Dimension PharmaLex (Cencora) bioaccess®
Public product Global MedTech regulatory consulting, authorized representative / license holder arranged in multiple markets LATAM medical device registration: registration, in-country holder, certified translations, government fees up to a stated cap, tecnovigilancia (import shipments quoted separately)
Geography Brazil and Mexico named; others not enumerated 19 LATAM markets
Public pricing Enterprise / statement of work Published two-part pricing: a one-time registration fee by country and class, plus an annual holder fee from year 2 (rate card)
Holder vs distributor Says that, as a specialist market representative, it keeps distribution arrangements independently structured Holds through its own in-country entities, with defined transfer provisions; the registration is never leverage
Bridge from a clinical trial None published Trial-to-Market continuity: the same partner that ran your FIH study can carry registration (see market access)

Where each one fits

If you are a large manufacturer already buying EU MDR and pharmacovigilance work from PharmaLex, adding Brazil or Mexico through the same account is fine.

The LATAM medical device registration service from bioaccess® is a different product. bioaccess® registers already FDA-cleared or CE-marked devices and holds them through its own in-country entities across 19 Latin American markets, including COFEPRIS, ANVISA, INVIMA, ANMAT, ISP and DIGEMID. Pricing is published as two parts: a one-time registration fee by country and device class, plus an annual holder fee from year 2 (see the rate card). Initial government fees and certified translations are included up to a stated cap, and the first 12 months of holder service are included (importer-of-record shipments are priced separately on the hub). For multi-country pricing, contact us or see the rate card. The registration is held for the manufacturer’s benefit, with defined transfer provisions if you ever change partners or set up your own entity.

One country and one local partner is enough? Hire the firm that publishes that job. Several LATAM labels under one holder who is not your distributor? Start at bioaccess® market access, read the LATAM importer of record guide, try the LATAM Launch Calculator, or request a registration quote.

Competitor facts from the PharmaLex (Cencora) public pages linked above, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented clients, prices or contacts.

← Back to Blog · Contact bioaccess®